

MiniReview

Triclosan: a widely used biocide and its link to antibiotics

Herbert P. Schweizer *

Department of Microbiology, Colorado State University, Fort Collins, CO 80523-1677, USA

Received 26 April 2001; received in revised form 4 June 2001; accepted 4 June 2001

First published online 26 June 2001

Abstract

Triclosan is the active ingredient in a multitude of health care and consumer products with germicidal properties, which have flooded the market in recent years in response to the public's fear of communicable bacteria. Although originally thought to kill bacteria by attacking multiple cellular targets, triclosan was recently shown to target a specific bacterial fatty acid biosynthetic enzyme, enoyl-[acyl-carrier protein] reductase, in Gram-negative and Gram-positive bacteria, as well as in the Mycobacteria. Triclosan resistance mechanisms include target mutations, increased target expression, active efflux from the cell, and enzymatic inactivation/degradation. These are the same types of mechanisms involved in antibiotic resistance and some of them account for the observed cross-resistance with antibiotics in laboratory isolates. Therefore, there is a link between triclosan and antibiotics, and the widespread use of triclosan-containing antiseptics and disinfectants may indeed aid in development of microbial resistance, in particular cross-resistance to antibiotics. © 2001 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved.

Keywords: Biocide; Antiseptic; Disinfectant; Resistance; Antibiotic cross-resistance; *Pseudomonas*; *Alcaligenes*

1. Introduction

The bisphenols are a class of compounds that exhibit a broad spectrum of antimicrobial activity. The two most widely used members of this group are triclosan (2,4,4'-trichloro-2'-hydroxydiphenylether) and hexachlorophene (2,2'-dihydroxy-3,5,6,3',5',6'-hexachlorodiphenylmethane) (Fig. 1). Because of toxicity concerns, the use of hexachlorophene in consumer products has been limited. Over the last 30 years, triclosan has become the most potent and widely used bisphenol [1]. Triclosan is used in many contemporary consumer and professional health care products. These include hand soaps, surgical scrubs, shower gels, deodorant soaps, health care personnel hand washes, hand lotions and creams, toothpastes, mouthwashes, and underarm deodorants [2]. Triclosan is also incorporated into fabrics and plastics, including children's toys, toothbrush handles, cutting boards, pizza-cutter and mop handles, as well as surgical drapes and hospital over-the-bed table tops. Searches of patent databases further reveal a multitude of suggested or actual uses of triclo-

san-impregnated materials, ranging from concrete with antimicrobial properties to bowling ball finger inserts.

Triclosan has been extensively tested in human and animal studies through acute toxicity, chronic toxicity, mutagenicity, reproduction and teratology investigations which were recently reviewed [2].

Triclosan is a synthetic, non-ionic, broad-spectrum antimicrobial agent, possessing mostly antibacterial, but also some antifungal and antiviral properties [2]. Triclosan is fairly insoluble in aqueous solutions, unless the pH is alkaline, and readily soluble in most organic solvents. It is chemically stable and can be heated up to 200°C for up to 2 h [1]. This thermal stability makes it suitable for incorporation into various reinforced plastic materials which are distributed under the trademark Microban®. Depending on formulation and application, triclosan is recognized by the United States Food and Drug Administration (FDA) as either an over-the-counter or a prescription drug. In addition, it is FDA-accepted for use as an antimicrobial pesticide for fungicide/fungistat and bacteriostat applications [2]. Triclosan, provided under its trade name Irgasan CH3565, is the active ingredient in Bacto *Pseudomonas* isolation agar used for selection of *Pseudomonas* since these bacteria are naturally resistant to the concentration (25 µg ml⁻¹) of triclosan used in the formulation of this selective medium. *Pseudomonas* isolation agar is rec-

* Tel.: +1 (970) 491 3536; Fax: +1 (970) 491 1815.

E-mail address: herbert.schweizer@colostate.edu (H.P. Schweizer).




Fig. 1. Structures of two biocides of the bisphenol family, triclosan and hexachlorophene.

commended for the isolation of *Pseudomonas* from industrial materials such as cosmetics and lotions (Difco Manual).

Although triclosan has been used for over 30 years, it was originally confined mostly to health care settings, and until very recently its use outside hospital settings was fairly limited. In the USA, triclosan has been used in underarm deodorants and deodorant soaps since the 1960s [3]. It was first introduced in the health care industry in a surgical scrub in 1972 and in toothpaste in Europe in 1985 [2]. The last decade has seen a rapid increase in the use of triclosan-containing products. A recent report estimated that between 1992 and 1999 over 700 consumer products with antibacterial properties, the vast majority of them containing triclosan, have entered the consumer market [4]. Due to its extensive use and stability, triclosan and its derivatives can now readily be detected in the environment and some food sources [5].

2. Mode of action

Until a specific target was described in 1998, triclosan was thought to act as a non-specific biocide by affecting membrane structure and function [6,7]. Isolated cell walls and whole cells of *Escherichia coli*, *Staphylococcus aureus* and *Pseudomonas aeruginosa* were shown to absorb triclosan by diffusion, and it was suggested that the degree of absorption was proportionate to the lipid content of cells [7]. Since *P. aeruginosa* had the highest lipid content it was concluded that this most likely explained its high-level triclosan resistance. In a subsequent study with an *E. coli* mutant that showed divalent cation-dependent triclosan resistance, an altered fatty acid profile was indeed observed [8]. It was reasoned that the altered fatty acid composition in this mutant may create a permeability barrier which is alterable by varying divalent cation concentrations. Although yet more recent studies again suggested

multiple cellular targets, their identities were never revealed at the molecular level [9]. The status quo in terms of identifying a cellular triclosan target was finally broken by several studies performed with *E. coli* [10,11], *P. aeruginosa* [12], *Mycobacterium smegmatis* [13,14], *Mycobacterium tuberculosis* [14] and *S. aureus* [15]. All of these studies showed that triclosan acts on a defined bacterial target in the bacterial fatty acid biosynthetic pathway, NADH-dependent enoyl-[acyl carrier protein] reductase (FabI), or its homolog InhA in *M. smegmatis* [13] and *M. tuberculosis* [14,16]. The determination of the crystal structure of the *E. coli* FabI–NAD⁺–triclosan complex confirmed that triclosan forms a stable ternary complex by interacting with amino acid residues of the enzyme active site [17–19]. Triclosan acts as a site-directed, picomolar inhibitor of enoyl-[acyl carrier protein] reductase by mimicking its natural substrate. The originally reported effects of triclosan on membrane structure and function are therefore explainable as secondary effects arising from specific inhibition of the fatty acid biosynthetic pathway, which in turn affects the many processes depending on lipid synthesis, e.g., phospholipid, lipopolysaccharide and lipoprotein synthesis. Although proponents of the multiple target hypothesis still argue that the higher concentrations of triclosan used in antiseptic products (2–20 mg ml⁻¹) cause cell lysis due to a multitude of effects, including inhibition of lipid, RNA, protein synthesis and membrane perturbations [9], no convincing experimental evidence supporting this hypothesis exists. Unfortunately, laboratory experiments using higher triclosan concentrations under defined conditions are hampered by the low solubility of triclosan in aqueous solutions (<0.2 mg ml⁻¹, depending on medium composition and pH).

3. Triclosan resistance mechanisms

Bacterial antibiotic resistance as a result of antibiotic use is a long-established and widely studied problem. The finding of a specific triclosan target spurred renewed and increasing attention to studies of responses of bacteria to biocides. As rightfully pointed out by Russell [20], there is particularly a clear need to establish whether there is a link between antibiotic and biocide resistance, and whether biocides can select for antibiotic resistance. Despite the fact that most of the efforts geared towards elucidating bacterial triclosan resistance mechanisms were concentrated on the last 3–4 years, it is already evident that bacteria use multiple mechanisms to develop resistance to this biocide, including target mutations, increased target expression, active efflux and degradative enzymes (Table 1).

3.1. Target mutations and increased target expression

In laboratory studies with triclosan, *fabI* mutations se-

Table 1
Mechanisms of triclosan resistance in bacteria

Bacterium	Mechanisms of resistance	Antibiotic cross-resistance	Reference
<i>E. coli</i>	<i>fabI</i> mutations; efflux	Yes ^a	[10,11,32]
<i>P. aeruginosa</i>	multiple efflux systems; <i>fabI</i> ^b	Yes	[12,34]
<i>S. aureus</i>	<i>fabI</i> mutations	No	[15]
<i>M. smegmatis</i>	<i>inhA</i> mutations	Yes	[13,14]
<i>M. tuberculosis</i>	<i>inhA</i> upregulating mutations	Yes	[14,21]
<i>P. putida</i> , <i>A. xylooxidans</i>	degradation	ND ^c	[36]

^a*fabI* mutations cause cross-resistance to diazaborines which are not used as therapeutics.

^bAlthough purified FabI is efficiently inhibited by triclosan, to date no in vivo triclosan resistance due to *fabI* mutations was observed; presumably, because efflux via multiple systems is the primary detoxification mechanism.

^cND, not determined. Although both species are resistant to multiple antibiotics, a link between the mechanisms responsible for triclosan resistance and antibiotic resistance has not yet been demonstrated.

lected by exposure to triclosan caused cross-resistance with other antimicrobial agents in *E. coli* [17]. This finding raised the fear that, in certain instances, biocides may share targets with antibiotics and imprudent and widespread use of this biocide may thus select resistance against clinically useful drugs. This notion has since been corroborated by several studies showing that some mutations affecting *InhA*, and leading to triclosan resistance in *M. smegmatis* [13] and *M. tuberculosis* [14,16], also caused resistance to isoniazid, a drug widely used for treatment of *M. tuberculosis* infections. Selection of spontaneous triclosan-resistant mutants in *M. smegmatis* caused mutations in the *inhA* gene which, like those in triclosan-resistant *fabI* mutants of *E. coli*, lie close to the NADH cofactor binding site [13,17]. In contrast, all triclosan-resistant mutants of *M. tuberculosis* examined to date contained a T to G point mutation in the putative ribosome binding site upstream of *mabA*, the gene located upstream of *inhA* [14]. This same mutation has been identified in isoniazid-resistant clinical isolates of *M. tuberculosis* and it results in an

eight-fold increase in transcription and/or translation of a reporter fusion [21]. The frequency at which spontaneous triclosan-resistant mutants arose in *M. smegmatis* and *M. tuberculosis* was $\sim 1 \times 10^{-9}$.

3.2. Detoxification via efflux pumps

3.2.1. Efflux pump families

Another, perhaps more widespread, mechanism of triclosan resistance is active efflux from the bacterial cell. Bacteria express diverse efflux pumps that are classified in mainly five families [22,23]. These include the resistance nodulation cell division (RND) family, the major facilitator superfamily (MFS), the small multidrug resistance (SMR) family, the ATP binding cassette (ABC) family and the multidrug and toxic compound extrusion (MATE) family. Well-characterized representatives of these families from Gram-positive and Gram-negative bacteria are shown in Fig. 2. All of these transporters catalyze active drug efflux and therefore require energy, mostly in




Fig. 2. Schematic illustration of the main types of bacterial drug efflux pumps. Illustrated are NorA, a member of the MFS, MexAB-OprM, a member of the RND family, and LmrA, a member of the ABC family. All systems extrude drugs in an energy-dependent manner, using either proton motive force or ATP. The two other types of efflux systems found in bacteria, MATE and SMR, look structurally similar to the MFS but are designated as distinct families based on phylogenetic diversity (MATE) or size (SMR). To date, only the RND systems have been shown to efflux triclosan. In *P. aeruginosa*, triclosan is pumped by several different RND-type systems and there is evidence that an outer membrane channel is not always required for triclosan detoxification. M indicates the outer membrane protein channel OprM.

the form of proton motive force, but some also in the form of ATP. The structure of RND-type drug efflux systems is most complex since they mediate drug efflux across two membranes. They possess components that form a channel spanning the entire cell envelope, an inner membrane translocase, an outer membrane protein channel and a periplasmic membrane fusion protein [23]. Most bacterial RND-type efflux systems are chromosomally encoded and the numbers range from no RND efflux operons identified in the chromosome of *M. tuberculosis* to 12 RND-type efflux operons encoded by the chromosome of *P. aeruginosa* [24]. It is now recognized that synergy between a low-permeability outer membrane and active efflux is the main cause for the high intrinsic and acquired resistance of *P. aeruginosa* to many antibacterials, including many clinically relevant antibiotics.

In *P. aeruginosa*, the expression of all but the MexAB-OprM-encoding efflux operon is tightly regulated and the other efflux systems are only expressed in regulatory mutants obtained by antibiotic exposure in vitro or in vivo (Fig. 3) [25–28]. Pump-expressing mutants isolated in the laboratory or obtained from clinical posttherapy isolates often contain mutations in adjacent regulatory genes. However, other negative regulatory factors must also be involved since many clinical isolates constitutively express various efflux pumps in the absence of identifiable up-

stream regulatory mutations, suggesting regulation by hitherto unidentified mechanisms [27,29,30]. In addition, the expression of some efflux pumps may also be subject to positive regulation, including at least one efflux operon whose transcription is quorum sensing-regulated [31].

The efflux pumps implicated in triclosan resistance thus far all belong to the RND family. In *E. coli* clinical and laboratory strains, triclosan is a substrate of the AcrAB-TolC multidrug efflux pump [32]. Although it has been known for quite some time that *P. aeruginosa* is extremely resistant to triclosan, this was mostly attributed to the relative impermeability of the outer membrane to antibacterial agents [33] and to its high cell wall lipid content. However, it has recently been shown that clinical and environmental *P. aeruginosa* isolates tested to date are intrinsically resistant to triclosan by virtue of constitutive expression of the MexAB-OprM efflux pump [34]. Mutants containing a deletion of the entire *mexAB-oprM* operon are triclosan-susceptible. Of the 12 RND-type efflux systems encoded by the *P. aeruginosa* genome, only four, i.e., MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXY-OprM (reviewed in [23]), have been characterized. Triclosan is a substrate of all but the MexXY-OprM system [34].

3.2.2. Triclosan selects for regulatory mutants expressing efflux pumps

Since triclosan is a substrate of most of the RND efflux pumps, exposure of bacterial cells to triclosan could select for regulatory mutants expressing these efflux pumps. If this were the case, then triclosan would simultaneously select for multiple antibiotic resistance since these efflux pumps are multidrug transporters. As an experimental model system, a triclosan-susceptible *P. aeruginosa* mutant was chosen which contains a $\Delta(mexAB-oprM)$ mutation. This strain does not express MexAB-OprM and, presumably, none of the other known efflux pumps. It does not grow in triclosan-containing medium but triclosan-resistant variants outgrow the culture in less than 24 h. These triclosan-resistant variants were obtained at relatively high frequencies (1×10^{-6}) and three out of three isolates tested expressed high levels of OprJ, the outer membrane channel of the MexCD-OprJ efflux pump. Expression of the MexCD-OprJ system was the only mechanism responsible for high-level triclosan resistance in these mutants since deletion of this efflux system resulted in triclosan-susceptible strains. All three mutants analyzed contained mutations in the upstream *nfxB* regulatory gene [34]. These mutations were similar to the types obtained by exposure to fluoroquinolone antibiotics (Table 2). These results confirmed that exposure of a susceptible *P. aeruginosa* strain to triclosan selects for multidrug-resistant variants, including resistance to clinically useful antibiotics. Triclosan is an excellent substrate for multidrug efflux pumps and indeed a tool for selecting pump regulatory mutations. Using triclosan, another mutant derivative expressing a hith-




Fig. 3. Regulation of efflux pump operon expression in *P. aeruginosa* using *mexCD-oprJ* as a model. A: In wild-type, the *nfxB*-encoded repressor represses transcription of the *mexCD-oprJ* operon. For various efflux systems, other negative and positive effectors have been suggested by clinical findings and laboratory studies. B: Most deregulated mutants contain mutations in the *nfxB* gene which leads to either no repressor synthesis (early termination by frame-shift) or synthesis of an inactive repressor (point mutations). Consequently, the *mexCD-oprJ* operon is constitutively transcribed. Alternatively, constitutive mutants could contain mutation in the *nfxB-mexC* intergenic regulatory regions; however, such mutants have not yet been described. Some clinical isolates constitutively express high levels of various efflux pumps although they do not contain mutations either in the structural genes for the cognate regulators or in the regulatory regions.

Table 2
Regulatory mutations selected by triclosan and fluoroquinolones that lead to efflux pump operon expression in *P. aeruginosa*

Regulatory gene	Efflux system expressed	Selecting antimicrobial	Amino acid changes in regulator	Reference
<i>nfxB</i>	MexCD-OprJ	triclosan	E28K (HTH) ^a L29W (HTH) ^b R42H (HTH) L88P	[34]
<i>nfxB</i>	MexCD-OprJ	norfloxacin	R42G (HTH)	[43]
<i>nfxB</i>	MexCD-OprJ	ciprofloxacin ^c	R82L	[40]
<i>mexL</i>	MexJK	triclosan	A47D (HTH)	Chuanchuen and Schweizer, unpublished

^aHTH, change affects putative helix-turn-helix DNA binding domain.

^bThese mutations were found in the same isolate.

^cIsolates from cystic fibrosis patients with long-term exposure to ciprofloxacin.

erto uncharacterized *P. aeruginosa* multidrug efflux system, MexJK, due to a mutation in its regulatory gene, *mexL*, was selected (Table 2; Chuanchuen and Schweizer, unpublished observations). Such mutants were obtained at a frequency of 1×10^{-8} . Although the MexJK system required the OprM outer membrane channel for antibiotic efflux, it did confer triclosan resistance in the absence of an outer membrane protein channel indicating efficient removal of triclosan from the cytoplasm.

3.3. Enzymatic degradation

Recently, two soil isolates, *Pseudomonas putida* strain TriRY and *Alcaligenes xylosoxidans* ssp. *denitrificans* strain TR1, were described that exhibited high levels of triclosan resistance [35]. These bacteria grew on medium containing 1% triclosan, a concentration found in many commercially available products. Preliminary investigations suggested that these isolates degrade triclosan [36]. Since *A. xylosoxidans* is a multiple drug-resistant emergent pathogen, especially in cystic fibrosis patients, this is of considerable concern. Triclosan degradation has also been demonstrated in *Sphingomonas* strain RD1 which is capable of mineralizing at least a portion of the triclosan molecule, as shown by the release of $^{14}\text{CO}_2$ from ^{14}C -labeled triclosan. Loss of the ability to mineralize triclosan resulted in susceptibility to this biocide [37]. Triclosan degradation therefore is another possible resistance mechanism and it is plausible that widespread use of triclosan increased the prevalence of these triclosan-resistant bacteria in the environment. It can be anticipated that further research in this area will reveal additional bacterial triclosan modification mechanisms. Two root fungi were recently shown to transform triclosan by either glucosylation or xylosylation of the hydroxyl group (Fig. 1) [38]. Similar modification mechanisms may also exist in bacteria.

4. The link between triclosan and antibiotics

Less than two years ago, statements such as “no connection exists between triclosan and antibiotic resistance” [39] could be found in the literature. The many recent

findings documented earlier in this review clearly link triclosan and antibiotics, and establish that triclosan can select for antibiotic resistance. This is best illustrated by two key findings. First, triclosan and antibiotics not only share multidrug efflux systems as a common mechanism of resistance but triclosan and antibiotics also cause expression of these efflux pumps by selecting similar mutations in the respective regulatory loci. Although *P. aeruginosa* is already triclosan-resistant, its resistance could theoretically be further increased by turning on additional efflux pumps. Clinical isolates that are resistant to high levels of antibiotics quite often express more than one efflux pump [30,40]. Second, in *M. tuberculosis* the same up-regulating mutation leading to isoniazid resistance in clinical isolates was also obtained by selecting triclosan resistance in the laboratory. While the connection between triclosan and antibiotics has clearly been established, we still do not know how this relates to the real world, i.e., we do not know how triclosan affects the microbial flora in all environments in which it is intensively used, from hospital to household settings. For example, widespread use of triclosan could lead to environments where bacteria like *Pseudomonas* and other triclosan-resistant bacteria thrive. While this still has to be proven, some anecdotal evidence supporting such a notion exists. Although after introduction of a new hand wash disinfectant containing 1% triclosan at a neonatal intensive care unit methicillin-resistant *S. aureus* was eliminated within 12 months, and the total number of multiply resistant Gram-negative organisms did not significantly change, *P. aeruginosa* was singled out as being reported three times more often within 14 months after the introduction of triclosan [41]. While the clinical significance of these findings was not further investigated, the data nonetheless suggest that some bacteria can compete, survive and propagate in an environment in which triclosan is routinely used.

It has been argued that the low-level resistance observed in in vitro selected triclosan-resistant mutants does not compare well to the real world since most commercially available products contain triclosan ranging from 2 to 20 mg ml⁻¹, far exceeding the minimal inhibitory and minimal bacteriocidal concentrations observed in these mutants. Therefore, it was reasoned, development of resis-

tance would be unlikely. While it may be true that germicidal products contain triclosan concentrations that are considerably higher than those used in laboratory experiments, several observations argue against the resulting conclusion that bacteria are unlikely to develop resistance because of these higher concentrations. First, some bacteria can tolerate and survive the triclosan concentrations found in most commercially available products, i.e., they are resistant to these high triclosan concentrations, and one can speculate that some of these resistance mechanisms may be transferable to other bacteria. Second, triclosan is extremely stable in the environment and low residual levels might encourage preferential survival of triclosan-resistant mutants, especially those expressing efflux pumps. This may be particularly important in environments where bacteria encounter materials designed to slowly release triclosan, e.g., around plastics and fabrics, or after dermal adsorption in the bloodstream and various organs, where triclosan has been found at concentrations that were only a fraction of those applied topically [42]. Many bacteria show minimal inhibitory concentrations high enough to be able to cope with such residual triclosan concentrations. *P. aeruginosa* expressing a single efflux pump exhibited a triclosan minimal inhibitory concentration of 0.13 mg ml⁻¹. This was measured in an aqueous environment at pH ~ 7 and the values are probably even higher in the presence of well-tolerated organic solvents or more alkaline pH values.

Given similar resistance mechanisms for triclosan and antibiotics, including target mutations, enzymatic inactivation/modification (degradation), increased target expression and, perhaps most importantly, widespread multidrug efflux pumps, it would be a surprise if the overuse of triclosan would not select for resistant strains. Since triclosan and antibiotics are linked, it is therefore quite possible that widespread use of triclosan may indeed compound antibiotic resistance. Clearly, the time has come to depart from the 'wait and see' attitude when considering a link between triclosan and antibiotics, and actively engage in a policy of increasing public awareness concerning the possible consequences of triclosan overuse, and to teach and heed the lessons we hopefully learned from antibiotic overuse.

Acknowledgements

Work in the author's laboratory is funded by a grant from the National Institutes of Health.

References

- [1] Bhargava, H.N. and Leonard, P.A. (1996) *Am. J. Infect. Control* 24, 209–218.
- [2] Jones, R.D., Jampani, H.B., Newman, J.L. and Lee, A.S. (2000) *Am. J. Infect. Control* 28, 184–196.
- [3] Jungermann, E. (1968) *J. Am. Oil Chem. Soc.* 45, 345–350.
- [4] Couzin, J. (1999) *US News*, <http://www.usnews.com/usnews/issue/990510/nycu/antibiotic.b2.html>.
- [5] Okumura, T. and Nishikawa, Y. (1996) *Anal. Chim. Acta* 325, 325.
- [6] Regos, J. and Hitz, H.R. (1974) *Zent.bl. Bakt. Hyg. I. Abt. Orig. A* 226, 390–401.
- [7] Meincke, B.E., Kranz, R.G. and Lynch, D.L. (1980) *Microbios* 28, 133–147.
- [8] Persino, R. and Lynch, D.L. (1982) *Microbios* 34, 41–58.
- [9] McDonnell, G. and Pretzer, D. (1998) *ASM News* 64, 670–671.
- [10] McMurry, L.M., Oethinger, M. and Levy, S.B. (1998) *Nature* 394, 531–532.
- [11] Heath, R.J., Yu, Y.-T., Shapiro, M.A., Olson, E. and Rock, C.O. (1998) *J. Biol. Chem.* 273, 30316–30320.
- [12] Hoang, T.T. and Schweizer, H.P. (1999) *J. Bacteriol.* 181, 5489–5497.
- [13] McMurry, L.M., McDermott, P.F. and Levy, S.B. (1999) *Antimicrob. Agents Chemother.* 43, 711–713.
- [14] Slayden, R.A., Lee, R.E. and Barry, C.E. (2000) *Mol. Microbiol.* 38, 514–525.
- [15] Heath, R.J., Li, J., Roland, G.E. and Rock, C.O. (2000) *J. Biol. Chem.* 275, 4654–4659.
- [16] Parikh, S.L., Xiao, G. and Tonge, P.J. (2000) *Biochemistry* 39, 7645–7650.
- [17] Heath, R.J., Rubin, J.R., Holland, D.R., Zhang, E., Snow, M.E. and Rock, C.O. (1999) *J. Biol. Chem.* 274, 11110–11114.
- [18] Roujeinikova, A. et al. (1999) *J. Mol. Biol.* 294, 527–535.
- [19] Stewart, M.J., Parikh, S., Xiao, G., Tonge, P.J. and Kisker, C. (1999) *J. Mol. Biol.* 290, 859–865.
- [20] Russell, A.D. (1999) *J. Hosp. Infect.* 43, S57–S68.
- [21] Mdluli, K., Sherman, D.R., Hickey, M.J., Kreiswirth, B.N., Morris, S., Stover, C.K. and Barry, C.E. (1996) *J. Infect. Dis.* 174, 1085–1090.
- [22] Putman, M., Van Ween, H.W. and Konings, W.N. (2000) *Microbiol. Mol. Biol. Rev.* 64, 672–693.
- [23] Zgurskaya, H.L. and Nikaido, H. (2000) *Mol. Microbiol.* 37, 219–225.
- [24] Stover, C.K. et al. (2000) *Nature* 406, 959–964.
- [25] Li, X.Z., Nikaido, H. and Poole, K. (1995) *Antimicrob. Agents Chemother.* 39, 1948–1953.
- [26] Poole, K. et al. (1996) *Mol. Microbiol.* 21, 713–724.
- [27] Westbrook-Wadman, S. et al. (1999) *Antimicrob. Agents Chemother.* 43, 2975–2983.
- [28] Koehler, T., Michea-Hamzehpour, M., Henze, U., Gotoh, N., Curty, L.K. and Pechere, J.C. (1997) *Mol. Microbiol.* 23, 345–354.
- [29] Ziha-Zafiri, I., Llanes, C., Koehler, T., Pechere, J.-C. and Plesiat, P. (1999) *Antimicrob. Agents Chemother.* 43, 287–291.
- [30] Pumbwe, L. and Piddock, L.J. (2000) *Antimicrob. Agents Chemother.* 44, 2861–2864.
- [31] Whiteley, M., Lee, K.M. and Greenberg, E.P. (1999) *Proc. Natl. Acad. Sci. USA* 96, 13904–13909.
- [32] McMurry, L.M., Oethinger, M. and Levy, S.B. (1998) *FEMS Microbiol. Lett.* 166, 305–309.
- [33] McDonnell, G. and Russell, A.D. (1999) *Clin. Microbiol. Rev.* 12, 147–179.
- [34] Chuanchuen, R., Beinlich, K., Hoang, T.T., Becher, A., Karkhoff-Schweizer, R.R. and Schweizer, H.P. (2001) *Antimicrob. Agents Chemother.* 45, 428–432.
- [35] Meade, M.J. and Callahan, T.M. (2000) Abstract presented at the 100th General Meeting of the American Society for Microbiology, Los Angeles, CA.
- [36] Waddell, R.L. and Meade, M.J. (2001) Abstract presented at the 101st General Meeting of the American Society for Microbiology, Orlando, FL.
- [37] Kagle, J. and Hay, A. (2001) Abstract presented at the 101st General Meeting of the American Society of Microbiology, Orlando, FL.

- [38] Hundt, K., Martin, D., Hammer, E., Jonas, U., Kindermann, M.K. and Schauer, F. (2000) *Appl. Environ. Microbiol.* 66, 4157–4160.
- [39] Tierno, P.M. (1999) *Am. J. Infect. Control* 27, 71–72.
- [40] Jalal, S., Ciofu, O., Hoiby, N., Gotoh, N. and Wretling, B. (2000) *Antimicrob. Agents Chemother.* 44, 710–712.
- [41] Webster, J., Faoagali, J.L. and Cartwright, D. (1994) *J. Paediatr. Child Health* 30, 59–64.
- [42] Moss, T., Howes, D. and Williams, F.M. (2000) *Food Chem. Toxicol.* 38, 361–370.
- [43] Okazaki, T. and Hirai, K. (1992) *FEMS Microbiol. Lett.* 97, 197–202.